Core Viewpoint - The Chinese traditional medicine industry is experiencing collective anxiety due to insufficient effective demand, accelerated industry transformation, policy changes, and intense market competition [1] Industry Performance Overview - The performance of traditional Chinese medicine companies in 2024 and the first quarter of 2025 shows a diverging trend, with some companies achieving stable growth through brand advantages and product innovation, while others face revenue declines and profit pressures [1][3] - In 2024, Baiyunshan led the industry with a revenue of 749.93 billion yuan, but experienced a slight decline of 0.69% year-on-year, indicating growth challenges for traditional giants [3][6] - Yunnan Baiyao and China Resources Sanjiu followed with revenues of 400.33 billion yuan and 276.17 billion yuan, reflecting year-on-year growth rates of 2.36% and 11.63%, respectively [3][6] - In the first quarter of 2025, leading companies continued to show growth, while trailing companies remained under pressure [1][6] Profitability Insights - Yunnan Baiyao reported a net profit of 47.67 billion yuan in 2024, maintaining a growth rate of 15.63%, while Pizhou's net profit reached 29.96 billion yuan, aligning with its revenue growth [6] - Daren Tang emerged as a "profit dark horse" with a net profit increase of 128.68% year-on-year, while Dong'e Ejiao's net profit grew by 25.57% due to product price increases and channel optimization [6][1] R&D and Sales Expenses - In 2024, the highest R&D investment was from Tianshili, amounting to 1.039 billion yuan, representing 12.23% of its revenue [6][7] - Sales expenses were highest for China Resources Sanjiu at 72.20 billion yuan, followed by Baiyunshan at 56.20 billion yuan [7] - The overall R&D investment among the top 20 companies indicates a need for improvement, especially in innovative drug development and modern Chinese medicine technology applications [7] Market Challenges and Strategic Responses - The unique product strategy, once a cash cow for many companies, is now facing challenges due to adjustments in medical insurance directories and expanded centralized procurement [9][10] - Companies like Step Long Pharmaceutical have reported significant losses due to high sales expenses and declining core product revenues [1][6] - The industry is witnessing a trend where companies are either "slimming down" by divesting non-core assets or "bulking up" through mergers and acquisitions to strengthen their market position [14][15] Future Outlook - The ongoing centralized procurement and market dynamics necessitate that companies balance pricing and market share while building brand moats [12][14] - Companies with unique proprietary formulas, such as Pizhou and Yunnan Baiyao, are better positioned to withstand market fluctuations compared to those reliant on single products without strong patent protection [11][12]

证券代码：600329 证券简称：达仁堂 公告编号：2025-016 号 津药达仁堂集团股份有限公司 关于召开2024年年度股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 召开的日期时间：2025 年 5 月 15 日 13 点 30 分 召开地点：中国天津市南开区白堤路 17 号达仁堂大厦会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 15 日 至2025 年 5 月 15 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六)融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者 的投票，应按照《上海证券交易所上市公司自律监管指引 ...

证券代码：600329 证券简称：达仁堂 公告编号：2025-016 号 津药达仁堂集团股份有限公司 关于召开2024年年度股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (一)股东大会类型和届次 2024年年度股东大会 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 15 日 13 点 30 分 召开地点：中国天津市南开区白堤路 17 号达仁堂大厦会议室 一、 召开会议的基本情况 股东大会召开日期：2025年5月15日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 15 日 至2025 年 5 月 15 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易 ...

目 录 现场会议召开时间：2025 年 5 月 15 日下午 1:30 会议方式：现场投票和网络投票相结合的方式 会议地点：中国天津市南开区白堤路 17 号达仁堂大厦会议室 津药达仁堂集团股份有限公司 2024 年度股东大会 会议资料 2025 年 5 月 15 日 2024 年度股东大会 文件目录 董事长工作报告 董事长 王磊 各位股东： 2024 年，达仁堂集团持续落实"一个中心、八大行动框架"工作主题，务 实推进品牌建设，市场营销，科技创新，精益生产等经营发展工作，持续提升品 牌力、产品力、服务力。 报告期内，在主业经营外，公司所持商业业务和联营企业股权资产有所调整。 公司以旗下全资子公司天津中新医药有限公司的全部股权作价，增资津药太平医 药有限公司，增资完成后，公司持有的商业业务资产以所持津药太平医药有限公 司 43.35%股权体现，为公司的联营公司，公司合并报表不再确认该业务资产收 入，仅按股权比例确认损益。2024 年公司年报确认商业业务的收入为 31.1 亿元， 同比下降 17.3%。 报告期内，医疗、医保、医药领域政策和市场不断发展，行业机遇与挑战并 存，国家统计局数据显示，全国规上医药制造业 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥1,455,299,952.25, a decrease of 30.22% compared to ¥2,085,588,390.55 in the same period last year[2] - Net profit attributable to shareholders was ¥374,247,760.07, down 3.38% from ¥387,326,165.82 year-on-year[2] - Total revenue for Q1 2025 was CNY 1,455,299,952.25, a decrease of 30.1% compared to CNY 2,085,588,390.55 in Q1 2024[16] - Net profit for Q1 2025 was CNY 371,785,463.35, a decrease of 3.0% from CNY 383,381,748.70 in Q1 2024[16] - Earnings per share for Q1 2025 was CNY 0.49, unchanged from CNY 0.50 in Q1 2024[17] Cash Flow - The net cash flow from operating activities increased significantly by 498.13%, reaching ¥355,525,720.74, compared to a negative cash flow of -¥89,299,402.45 in the previous year[2] - Operating cash flow for Q1 2025 was CNY 355,525,720.74, compared to a negative cash flow of CNY -89,299,402.45 in Q1 2024[20] - Cash inflow from operating activities was CNY 1,218,073,248.73, down from CNY 1,737,890,346.16 in Q1 2024[20] - The company experienced a net decrease in cash and cash equivalents of -$1.49 billion during the period[21] - Cash and cash equivalents decreased from ¥2,944,432,686.21 to ¥1,454,568,332.22[11] Assets and Liabilities - Total assets at the end of the reporting period were ¥11,167,867,980.27, reflecting a 3.71% increase from ¥10,768,625,044.29 at the end of the previous year[3] - The total assets as of March 31, 2025, are ¥11,167,867,980.27, compared to ¥10,768,625,044.29 at the end of 2024[12] - The total liabilities increased from ¥4,160,561,516.07 to ¥5,471,481,096.13 over the same period[12] - Total liabilities as of the reporting date were CNY 2,946,260,395.43, an increase from CNY 2,918,688,717.32 year-over-year[16] - The company's total current assets as of March 31, 2025, amount to ¥5,696,386,884.14, a decrease from ¥6,608,063,528.22 as of December 31, 2024[11] Shareholder Information - The total number of common shareholders at the end of the reporting period is 52,324[8] - Tianjin Pharmaceutical Group Co., Ltd. is the largest shareholder, holding 331,120,528 shares, which accounts for 42.997% of the total shares[9] - ABN AMRO CLEARING BANK N.V. holds 72,763,900 shares, representing 9.449% of the total shares[9] - The company has not disclosed any significant changes in shareholder relationships or actions among the top shareholders[9] Investment and Financing - The company's investment income decreased by 31.36% due to a reduction in the equity stake in a joint venture, resulting in lower returns[6] - The company's short-term borrowings increased by 234.51%, indicating a rise in reliance on short-term financing[5] - The company reported a short-term loan of ¥72,431,607.62, up from ¥21,653,247.51[12] - The net cash flow from investing activities was -$1.85 billion, with total cash outflows from investing activities amounting to $2.42 billion[21] - The company reported a cash inflow of $300 million from borrowing activities[21] Future Outlook - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[2] - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[21] - The company’s cash flow management strategies will be crucial in navigating the upcoming financial adjustments and market conditions[21]

Group 1 - The pharmaceutical industry has undergone profound changes in both market demand and industrial environment, with consumers now seeking not only treatment but also prevention and a better quality of life [1][3] - The industry is moving towards standardization and compliance, which is essential for the development of new productive forces within companies [3] - Tianjin Yao Da Ren Tang has a range of well-known traditional Chinese medicine products, including the well-known Su Xiao Jiu Xin Wan, and operates four time-honored brands [3] Group 2 - The company emphasizes the importance of cultivating its own new productive forces to strengthen and refine its industrial chain [3] - The company is pursuing full-process standardization in the cultivation, extraction, production, and sales of traditional Chinese medicine to address safety, effectiveness, stability, and controllability [3] - The company has begun to explore international markets since 2022, achieving some results in its three years of international market layout [3]

(一)股东大会类型和届次 2025年第一次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的方式 证券代码：600329 证券简称：达仁堂 公告编号：2025-015号 津药达仁堂集团股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 网络投票起止时间：自2025年6月9日 召开的日期时间：2025年6月9日 14点 00分 (四)现场会议召开的日期、时间和地点 至2025年6月9日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东大会召开当日的交易时间 段，即9:15-9:25,9:30-11:30，13:00-15:00；通过互联网投票平台的投票时间为股东大会召开当日的9:15- 15:00。 (六)融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投票，应按照《上海证券交易 所上市公司自律监管指 ...

证券代码：600329 证券简称：达仁堂 公告编号：2025-015 号 津药达仁堂集团股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 6 月 9 日 14 点 00 分 召开地点：中国天津市南开区白堤路 17 号达仁堂大厦会议室 股东大会召开日期：2025年6月9日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (一)股东大会类型和届次 2025年第一次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 无 二、 会议审议事项 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 9 日 至2025 年 6 月 9 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 ...

4月15日晚间，达仁堂发布公告称，分别向赫力昂（中国）转让天津史克4.6%股权，向Haleon CH SARL转让天津史克7.4%股权，合计交易价格约为16.23亿元人民币。本次转让完成后，公司不再持有 天津史克股权。 初步测算，本次交易价格对应的标的资产估值存在35%溢价。这将为达仁堂带来约15.4亿元的投资收 益，税后归母净利润将增加13亿元，从短期来看，可以提升达仁堂的2025年净利润。 值得一提的是，去年9月，达仁堂也曾溢价转让了其持有的天津史克13%股权，入账收益17.59亿元。这 笔收益还导致达仁堂当年净利润实现翻倍增长达22.29亿元，同比增长125.94%。但其扣非净利润却只有 7.46亿元，同比下滑21.62%，是七年来首次出现负增长。 业绩层面上，达仁堂的营收已经连续两年下滑。具体来看，达仁堂的核心产品只有清咽滴丸在2024年实 现销售量的增长，卖出约960万盒，同比增长37.06%，其余产品同比均为负增长。其中，京万红软膏以 26.88%的降幅领跌，紫龙金片、通脉养心丸、清肺消炎丸等产品销量跌幅普遍超过10%，甚至速效救心 丸、安宫牛黄丸这两款产品销量下滑产量却反增。 据悉，天津史克有着 ...

Core Viewpoint - Daren Tang plans to sell its 12% stake in Tianjin Sihke Pharmaceutical Co., Ltd. for a total price of 1.623 billion yuan, marking a complete exit from the shareholder list of Tianjin Sihke [1] Group 1: Transaction Details - The transaction is expected to bring an investment gain of 1.54 billion yuan for the current period [1] - Daren Tang's market capitalization is 23.462 billion yuan, with a previous closing price of 30.47 yuan [1] - The stake is being sold to Helion (China) Co., Ltd. and Haleon CH SARL [1] Group 2: Financial Implications - The sale represents a significant short-term financial gain for Daren Tang, which had previously earned 245 million yuan from this investment in 2023, accounting for 25% of the company's net profit [1] - The funds from the transaction are intended for business expansion, including strategic acquisitions, R&D projects, new product development, market expansion, and general corporate purposes [1] Group 3: Business Performance Challenges - Daren Tang's main business performance is declining, with industrial revenue of 4.491 billion yuan, down 437 million yuan year-on-year, and commercial revenue of 3.113 billion yuan, down 649 million yuan year-on-year [2] - Key products have seen a decrease in sales, with a non-recurring net profit dropping by 21.62% to 746 million yuan, indicating a fatigue in main business growth [2] - The complete divestment from Tianjin Sihke may pose challenges for Daren Tang in terms of strategic execution and the ability to cultivate new business opportunities [2] Group 4: Future Growth Considerations - The ability of Daren Tang to effectively utilize the proceeds from the sale to drive future growth will be critical [2] - Without a clear industrial logic and implementation path, there is a risk of resource waste and management challenges with the large sum of cash on hand [2] - The sale of Tianjin Sihke is seen as a starting point, with the real challenge lying in how to leverage the funds for the next growth phase [2]